Skip to main content

Market Overview

Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease

Share:
  • Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease. Darvadstrocel received an orphan drug designation in Japan in March 2019.
  • The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel. Takeda will present the data from Darvadstrocel-3002 at a scientific meeting soon. 
  • Darvadstrocel is approved in the European Union, Israel, Switzerland, and the U.K. to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease when fistulas have shown an inadequate response to at least one conventional or biologic therapy.
  • Price Action: TAK shares closed 1.7% higher at $17.71 on Tuesday.
 

Related Articles (TKPHF + TAK)

View Comments and Join the Discussion!

Posted-In: Crohn's DiseaseBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com